Abstract:
En
|
Text:
En
|
PDF:
En
ABSTRACT Objective Sulfonylureas have been used to improve performance in strength sports. However, this hypothetical effect has not been proven. We examined the ergogenic acute effect of gliclazide on resistance training performance and muscle recovery. Subjects and methods We conducted a double-blind, randomized, crossover pilot study with 10 healthy resistance-trained adults (29.3 ± 4.4 years), nonusers of anabolic steroids. The participants were randomized to two exercise sessions. In the first session, five participants received placebo and the other five received gliclazide modified release, both administered 8 hours before the session. Session two was performed in a crossover fashion a week later. The volume load was calculated as the maximum number of repetitions of four sets multiplied by load (65% 1-RM). Blood samples were collected before and after exercise, as well as 24 hours and 48 hours after exercise for measurement of creatine kinase (CK-MM) and lactate dehydrogenase (LDH) activity. Blood glucose was measured with a glucometer before, during, and after the exercise sessions. Results Gliclazide did not enhance volume load for bench press (placebo: 2,698.0 ± 923.0 kg; gliclazide: 2,675.0 ± 1,088.0 kg; p = 0.073) or leg press (placebo: 10,866.0 ± 2,671.0 kg; gliclazide: 10,817.0 ± 2,888.0 kg; p = 0.135). However, CK-MM (-27.7%; p = 0.034) and LDH (-21.1%; p = 0.021) activities were decreased with gliclazide 48 hours after exercise. There was also a decrease in blood glucose in the gliclazide compared with the placebo session (p = 0.018). Conclusion Gliclazide did not enhance performance in a single resistance training session, but promoted faster muscle recovery. The decrease in blood glucose post-exercise with gliclazide was an undesirable effect that could lead to long-term glucose metabolism disorders. Registered in ClinicalTrials.gov under number NCT04443777. sports However proven recovery doubleblind, doubleblind double blind, blind double-blind 1 resistancetrained trained 29.3 293 29 3 (29. 44 4 4. years, years , years) steroids sessions release later 65% 65 (65 1RM. 1RM RM . 1-RM) 2 CKMM CK MM (CK-MM (LDH activity during (placebo 26980 698 0 2,698. 9230 923 923. kg 26750 675 2,675. 10880 088 1,088. 0.073 0073 073 108660 866 10,866. 26710 671 2,671. 108170 817 10,817. 28880 888 2,888. 0.135. 0135 0.135 135 0.135) 27.7% 277 27 7 (-27.7% 0.034 0034 034 21.1% 211 21 (-21.1% 0.021 0021 021 0.018. 0018 0.018 018 0.018) postexercise post longterm long term disorders ClinicalTrialsgov ClinicalTrials gov NCT04443777 NCT 29. (29 6 (6 1-RM 2698 69 2,698 92 2675 67 2,675 1088 08 1,088 0.07 007 07 10866 86 10,866 2671 2,671 10817 81 10,817 2888 88 2,888 013 0.13 13 27.7 (-27.7 0.03 003 03 21.1 (-21.1 0.02 002 02 001 0.01 01 NCT0444377 (2 ( 269 2,69 9 267 2,67 108 1,08 0.0 00 1086 10,86 1081 10,81 288 2,88 0.1 27. (-27. 21. (-21. NCT044437 26 2,6 1,0 0. 10,8 28 2,8 (-27 (-21 NCT04443 2, 1, 10, (-2 NCT0444 (- NCT044 NCT04 NCT0